Abstract
Stroke is the third common cause of death and the most common cause of adult disability. Approximately 80% of all strokes are ischemic (brain infarction). The only approved acute therapy is intravenous thrombolysis with tissue plasminogen activator within 3 h of symptom onset but only a small percentage of all ischemic stroke patients can receive this therapy. Therefore, novel therapeutic approaches directed at the pathophysiological mechanisms involved in ischemic brain injury are urgently needed. To this end several experimental stroke models were developed. These models are indispensable for understanding the pathophysiology of brain ischemia and to develop novel drugs and investigative methodology. This review considers the most commonly used ischemic stroke models (including preconditioning models) in rodents emphasizing their advantages and disadvantages. Since none of the models can perfectly simulate human stroke, researchers must interpret experimental findings carefully.
Keywords: Rat, mouse, infarction, brain, ischemia, therapy, ischemic tolerance, magnetic resonance imaging, preconditioning
Current Pharmaceutical Design
Title: Rodent Models of Ischemic Stroke: A Useful Tool for Stroke Drug Development
Volume: 14 Issue: 4
Author(s): Aysan Durukan, Daniel Strbian and Turgut Tatlisumak
Affiliation:
Keywords: Rat, mouse, infarction, brain, ischemia, therapy, ischemic tolerance, magnetic resonance imaging, preconditioning
Abstract: Stroke is the third common cause of death and the most common cause of adult disability. Approximately 80% of all strokes are ischemic (brain infarction). The only approved acute therapy is intravenous thrombolysis with tissue plasminogen activator within 3 h of symptom onset but only a small percentage of all ischemic stroke patients can receive this therapy. Therefore, novel therapeutic approaches directed at the pathophysiological mechanisms involved in ischemic brain injury are urgently needed. To this end several experimental stroke models were developed. These models are indispensable for understanding the pathophysiology of brain ischemia and to develop novel drugs and investigative methodology. This review considers the most commonly used ischemic stroke models (including preconditioning models) in rodents emphasizing their advantages and disadvantages. Since none of the models can perfectly simulate human stroke, researchers must interpret experimental findings carefully.
Export Options
About this article
Cite this article as:
Durukan Aysan, Strbian Daniel and Tatlisumak Turgut, Rodent Models of Ischemic Stroke: A Useful Tool for Stroke Drug Development, Current Pharmaceutical Design 2008; 14 (4) . https://dx.doi.org/10.2174/138161208783497688
DOI https://dx.doi.org/10.2174/138161208783497688 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cell Therapies for the Lysosomal Storage Diseases – the Quintessential Neurodegenerative Diseases
Current Stem Cell Research & Therapy Role of Nitric Oxide Signaling Pathways in Brain Injuries
Current Chemical Biology Nutraceuticals for Promoting Longevity
Current Nutraceuticals Neonatal and Long-Term Consequences of Fetal Growth Restriction
Current Pediatric Reviews A Review on Cellular and Molecular Mechanisms Linked to the Development of Diabetes Complications
Current Diabetes Reviews Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases
CNS & Neurological Disorders - Drug Targets Aquaporin Biology and Nervous System
Current Neuropharmacology Metabolic Fate of Endocannabinoids
Current Neuropharmacology Meet Our Regional Editor
CNS & Neurological Disorders - Drug Targets Pharmacokinetics/Pharmacodynamics Model-Supported Early Drug Development
Current Pharmaceutical Biotechnology P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Vascular Effects of Phytoestrogens and Alternative Menopausal Hormone Therapy in Cardiovascular Disease
Mini-Reviews in Medicinal Chemistry The Role of Mitogen-Activated Protein Kinases in Asthma
Current Immunology Reviews (Discontinued) Blockage of Central Sphingosine-1-phosphate Receptor does not Abolish the Protective Effect of FTY720 in Early Brain Injury after Experimental Subarachnoid Hemorrhage
Current Drug Delivery 2-(ω-Carboxyethyl)pyrrole Antibody as a New Inhibitor of Tumor Angiogenesis and Growth
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetic Distribution of 67Cu(II)2[3,5-Diisopropyl(Carboxy- 14C)Salicylate]4 Among Murine Tissues
Current Medicinal Chemistry Neurodegenerative Diseases of the Retina and Potential for Protection and Recovery
Current Neuropharmacology Mechanistic Insights into the Antileukemic Activity of Hyperforin
Current Cancer Drug Targets Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
Current Cancer Drug Targets Mechanisms of Control of Neuron Survival by the Endocannabinoid System
Current Pharmaceutical Design